Âý²¡¶¾°ü×°
ЧÀÍÏêÇé
| ЧÀÍÀàÐÍ | ÇóýÂý²¡¶¾/¹ý±í´ïÂý²¡¶¾/×ÌÈÅÂý²¡¶¾/ÎĿⲡ¶¾ |
|---|---|
| ½»¸¶±ê×¼ | 1.µÎ¶È±¨¸æ2.ͼÆ×3.Âý²¡¶¾ |
| ÖÜÆÚ | ¿ìÖÁ3ÖÜ |
| ¼ÛÇ® |
¹ý±í´ïÂý²¡¶¾£º µÍÖÁ3680Ôª ÇóýÂý²¡¶¾£º 1820Ôª/Ìõ£¬£¬£¬£¬5460Ôª£¨Èý±£Ò»£© ×ÌÈÅÂý²¡¶¾£º 1820Ôª/Ìõ£¬£¬£¬£¬5460Ôª£¨Èý±£Ò»£© |
ЧÀÍÓÅÊÆ
¸ßЧµÄ°üװϵͳ
¿ÆÑ§µÄµÎ¶È²â¶¨ÒªÁì
¼«¸ßµÄÇå¾²ÐÔ
ÍŶÓÂÄÀú¸»ºñ
ЧÀÍÀàÐÍ
| ÇóýÂý²¡¶¾ | ½«CRISPR/Cas9»ùÒòÇóýϵͳµÝËÍÖÁϸ°ûÖУ¬£¬£¬£¬ÊµÏÖÄ¿µÄ»ùÒòµÄÓÐÓÃÇóý |
|---|---|
| ¹ý±í´ïÂý²¡¶¾ | ½«ÍâÔ´»ùÒòƬ¶ÏµÝËÍÖÁϸ°ûÖУ¬£¬£¬£¬ÊµÏÖ»ùÒòƬ¶Ï¸ßЧ¡¢Îȹ̵رí´ï |
| ×ÌÈÅÂý²¡¶¾ | ½«shRNA×ÌÈÅϵͳµÝËÍÖÁϸ°ûÖУ¬£¬£¬£¬ÊµÏÖÄ¿µÄ»ùÒòºã¾Ã¡¢Îȹ̵ØÇýµ |
| ÎĿⲡ¶¾ | ½«CRISPR/CasÎÄ¿âµÝËÍÖÁϸ°ûÖУ¬£¬£¬£¬¹¹½¨»ùÒò±à¼»ìÏýϸ°û³Ø |
½»¸¶±ê×¼
| »ùÒòÇóý²¡¶¾¡¢¹ý±í´ï²¡¶¾¡¢×ÌÈŲ¡¶¾ | CRISPR/Cas9ÎÄ¿âÂý²¡¶¾ |
|---|---|
|
µÎ¶È±¨¸æ |
µÎ¶È±¨¸æ |
| ÖÊÁ£Í¼Æ× | ÖÊÁ£Í¼Æ× |
|
²Ù×÷˵Ã÷ |
ÎÄ¿âÂý²¡¶¾£¨ ≥1×10^6 TU/mL,½»¸¶¹æ¸ñ£º1×10^8 TU¡¢5×10^8 TU¡¢1×10^9 TU£© |
| Âý²¡¶¾£¨µÎ¶È£º≥1×10^6 TU/mL£¬£¬£¬£¬1 mL£© |
ЧÀÍÁ÷³Ì
Ó¦Óð¸Àý

Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
²Î¿¼ÎÄÏ×
ͨ¹ýSENP1-shRNAÂý²¡¶¾¹¹½¨SENP1Çõ͵ĽºÖÊÁö¸Éϸ°û£¨GSCs£©
±¾Ñо¿Ì½ÌÖ SENP1 ½éµ¼µÄÈ¥SUMO»¯ÔÚȱÑõÌõ¼þ϶ԽºÖÊÁö¸Éϸ°û£¨GSCs£©¶ñÐÔÐÐΪµÄÓ°Ïì¼°ÆäÁÙ´²¼ÛÖµ¡£¡£¡£È±ÑõÌõ¼þÏ£¬£¬£¬£¬HIF1α Éϵ÷¼¤»î GSCs ÖÐµÄ Wnt/β-Á¬»·ÂѰ×ÐźÅͨ·£¬£¬£¬£¬Ö§³Ö½ºÖÊĸϸ°ûÁö£¨GBM£©Éú³¤¡£¡£¡£SENP1 ½éµ¼µÄÈ¥SUMO»¯ÎÈ¹Ì HIF1α ºÍ β-Á¬»·ÂѰ׵ıí´ï£¬£¬£¬£¬Ôö½ø GSCs Òý·¢µÄÖ×ÁöÐγɡ£¡£¡£Ê¹ÓÃÂý²¡¶¾°ü×°µÄ SENP1 shRNA ϵ÷ GSCs ÖÐµÄ SENP1 ±í´ï£¬£¬£¬£¬Ð§¹ûÏÔʾ GSCs µÄÔöÖ³ºÍ·Ö½âÏ÷Èõ£¬£¬£¬£¬Ö×Áö±¬·¢ïÔÌ¡£¡£¡£HIF1α ÓÕµ¼µÄ Wnt/β-Á¬»·ÂѰ׼¤»îÒÀÀµÓÚ SENP1 ½éµ¼µÄÈ¥SUMO»¯£¬£¬£¬£¬Ôö½ø GSC Çý¶¯µÄ GBM ÔöÌí¡£¡£¡£Ñо¿Åú×¢£¬£¬£¬£¬°ÐÏò SENP1 ¿ÉÄÜÓÐÓÃÌá¸ß GBM µÄÖÎÁÆÐ§¹û¡£¡£¡£
ͨ¹ýCBLB-OEÂý²¡¶¾¹¹½¨CBLB¹ý±í´ïµÄ293T ϸ°û
³¦µÀ΢ÉúÎïȺºÍ´úлÎïµÄÌØ¶¨¸Ä±äÓë¼±ÐÔÐ£ËÀ£¨AMI£©Ïà¹Ø£¬£¬£¬£¬CBLB ¿ÉÄÜÔÚÆäÖÐʩչÖ÷Òª×÷Óᣡ£¡£È»¶ø£¬£¬£¬£¬ÕâЩÏ໥×÷ÓõÄÏêϸ»úÖÆÉÐδ³ä·ÖÑо¿£¬£¬£¬£¬µ¼ÖÂÃ÷È·ÉϵÄÖØ´óȱ·¦¡£¡£¡£±¾Ñо¿Ö¼ÔÚͨ¹ýת¼×é²âÐò¡¢16S rDNA ºÍ·Ç°ÐÏò´úлÎïÆÊÎö£¬£¬£¬£¬Ì½ÌÖ CBLB ¸ÉÔ¤¶Ô AMI СÊóµÄÓ°Ïì¡£¡£¡£Ñо¿ÍŶӽÓÄɶà×éѧ×ۺϲßÂÔ£¬£¬£¬£¬°üÀ¨½« CBLB Âý²¡¶¾°ü×°ÔØÌåתȾÈë 293T ϸ°û£¬£¬£¬£¬È»ºó¶Ô AMI СÊó¾ÙÐиÉÔ¤£¬£¬£¬£¬²¢¾ÙÐв¡ÀíȾɫ¡¢·à±ã 16S rDNA ²âÐòºÍѪÇå·Ç°ÐÏò´úл×éѧÆÊÎö¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬CBLB ¸ÉÔ¤ÏÔÖøïÔÌÁËСÊóÐÄÔ๣ËÀÇøµÄÑ×֢ϸ°û½þÈóºÍ½ºÔÏËάÐγɣ¬£¬£¬£¬²¢µ¼ÖÂ΢ÉúÎïȺ¡¢´úлÎïºÍ²î±ð±í´ï»ùÒò£¨DEGs£©µÄÒªº¦×ª±ä¡£¡£¡£ÕâÅú×¢ CBLB ÔÚ AMI µ÷¿ØÖпÉÄÜÆðÖ÷Òª×÷Óᣡ£¡£Ñо¿È·ÈÏÁË CBLB ¸ÉÔ¤ºó²î±ð»ùÒò¡¢´úлÎïºÍ΢ÉúÎïȺÔÚ AMI µ÷¿ØÖеÄDZÁ¦£¬£¬£¬£¬ÎªÎ´À´Ì½Ë÷ CBLB µÄÖÎÁÆÓ¦ÓÃÌṩÁË»ù´¡¡£¡£¡£
¾«Ñ¡¿Í»§ÎÄÕÂ
Deep whole-genome analysis of 494 hepatocellular carcinomas
È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£±ðµÄ£¬£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰе㡣¡£¡£

ºòÑ¡Çý¶¯Òò×Ӹſö
Targeted Macrophage CRISPR-Cas13 mRNA Editing in Immunotherapy for Tendon Injury
¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¶Ô´Ë£¬£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬Ðγɡ£¡£¡£±ðµÄ£¬£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼²ßÂÔµÄʾÒâͼ
Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophage and bone repair via MAPK/JNK inhibition and OXPHOS activation
¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźţ¬£¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬£¬ïÔÌÉñ¾ÔªµòÍö£¬£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£±ðµÄ£¬£¬£¬£¬¾Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£

ͼ½âÕªÒª
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters
S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬£¬¿É¼á³ÖÔÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬£¬¹ØÓڽˮ¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£

ͼ½âÕªÒª
Dumbbell probe initiated multi-rolling circle amplification assisted CRISPR/Cas12a for highly sensitive detection of clinical microRNA
ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£

ͼ½âÕªÒª
FAQ
ʲôÊÇÂý²¡¶¾°ü×°£¿£¿£¿£¿£¿£¿
Âý²¡¶¾×ªµ¼ºó£¬£¬£¬£¬Ï¸°û״̬ºÜ²îÉõÖÁ·ºÆð´ó×ÚéæÃü£¬£¬£¬£¬ÔõÑù½â¾ö£¿£¿£¿£¿£¿£¿
1.²¡¶¾µÎ¶È¹ý¸ß£º¸ßµÎ¶ÈµÄÂý²¡¶¾¿ÉÄܵ¼ÖÂϸ°û¶¾ÐÔ£¬£¬£¬£¬Ê¹Ï¸°ûÎÞ·¨Õý³£Éú³¤¡£¡£¡£½â¾ö¼Æ»®ÊǽµµÍ²¡¶¾µÄµÎ¶È£¬£¬£¬£¬¾ÙÐÐһϵÁÐÏ¡ÊÍʵÑ飬£¬£¬£¬ÕÒµ½Ò»¸ö¼ÈÄÜÓÐÓÃתȾÓÖ²»Ó°Ïìϸ°ûÉú³¤µÄµÎ¶È
2.ϸ°û״̬²»¼Ñ£ºÑ¬È¾Ç°Ï¸°ûµÄ¿µ½¡×´Ì¬¿ÉÄÜÓ°ÏìѬȾºóµÄÉú³¤¡£¡£¡£½â¾ö¼Æ»®ÊÇÈ·±£Ï¸°ûÔÚ×î¼Ñ״̬ϾÙÐÐѬȾ£¬£¬£¬£¬ÀýÈçÔÚѬȾǰ24Сʱ»»ÐÂÏÊ×÷Óý»ù£¬£¬£¬£¬²¢È·±£Ï¸°ûÃܶÈÊÊÖÐ
ÍêÃÀÕæÈË